Antiphospholipid Syndrome Criteria Panel - Machaon Diagnostics
New test available: mHam 2.0 – Complement-Dependent Cell Killing Assay

Test Directory

Home Test Search Results Antiphospholipid Syndrome Criteria Panel
Antiphospholipid Syndrome Criteria Panel

Justification

This panel will detect laboratory abnormalities characteristic of Antiphospholipid Syndrome (APS), including the presence of a lupus anticoagulant, antibodies against the membrane phospholipid cardiolipin (IgG, IgM and IgA isotypes) and antibodies against B2GP1 (IgG, IgM and IgA isotypes). Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening form of APS characterized by the presence of a triple-positive APS lab work-up. Detecting a single, double, or triple positive result can significantly change patient management. Lupus anticoagulant and antiphospholipid antibodies increase the risk of arterial thrombosis, venous thrombosis, thrombocytopenia and recurrent miscarriage.

Panel Component Tests

aPTT-LA (Lupus Sensitive) Russell Viper Venom Time (dilute) Anticardiolipin Antibody (IgG, IgM, IgA) Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA)

STAT: < 48 hours (M-F)

Clot-based, CIA

Draw Tube: Blue Top

Draw Tube: Red Top

Sample Type: Citrated Plasma and Serum

Specimen Requirements

Sample Type Volume Required Minimum Volume Stability
PREFERRED Citrated Plasma and Serum Three aliquots, 1mL each (Citrated Plasma);One aliquot, 1mL (Serum) Three aliquots, 0.5mL each (Citrated Plasma);One aliquot, 0.5mL (Serum) Frozen (-20C): 2 weeks
Frozen (-80C): 6 months
ALTERNATIVE - - - -
REJECTION CRITERIA Thawed in transit if shipped frozen, refrozen, clotted sample
SPECIAL INSTRUCTIONS -

General Information

METHODOLOGY Clot-based, CIA
STAT TAT < 48 hours (M-F)
STAT TAT Performance > 90% of results released in 48 hours
ROUTINE TAT < 1 week
ALTERNATIVE NAMES APS Panel, Lupus Anticoagulant (LA), Antiphospholipid Antibody testing, CAPS work-up
DESCRIPTION Antiphospholipid antibodies are present in Antiphospholipid Syndrome (APS) and may be detected in both solid (CIA) and plasmatic-based tests. Beta-2 Glycoprotein I (B2GPI) antibodies measured above 20 CU are considered positive and are associated with APS as described by international consensus and Harris et al [1,2] Persistently elevated levels of B2GPI antibodies are associated with an increased risk of vascular thrombosis and obstetrical complications [3,4]. This assay employs an FDA-approved, chemiluminescent immunoassay (CIA) method and reports in arbitrary chemiluminescent units (CU).
LIMITATIONS -
NORMAL RANGE Interpretation: Normal
ASSOCIATED TESTING -
REFERENCES

1. Ruiz-Irastorza G et al. Antiphospholipid syndrome. Lancet 2010; 376:1498.

2. Giannakopoulos B et al. How we diagnose the antiphospholipid syndrome. Blood 2009; 113:985.

3. Pengo V et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737.

4. Bertolaccini ML et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64:1639.

5. Vila P et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72:209.
SAMPLE REPORT Upon request
NEW YORK STATE APPROVED Yes

Test Codes

ORDER CODE P1212
CPT CODE 86147x3, 86146x3, 85613, 85730
LOINC CODE 3181-5, 3182-3, 5076-5